Novartis Can Sell Neupogen Copy in US in September

A US federal appeals court has ruled that Swiss drugmaker Novartis can begin selling Zarxio, its lower-cost generic version of an Amgen drug, on the US market starting in September. This thwarts a bid by the US biotech company to further delay the launch.

In what was called a landmark decision, the US Food and Drug Administration (FDA) in March gave Novartis the green light to sell the generic version of Amgen’s Neupogen – used to boost blood cells in cancer patients. It was the first biosimilar to be approved by the regulatory agency.

A dispute subsequently ensued over the length of the notice the producer of a biosimilar must give to the original drugmaker after receiving FDA approval before starting the marketing process.

In its Jul. 21 ruling the court said companies marketing new biosimilars must give 180 days advance notice. Novartis had argued that the notice could be given prior to FDA approval.

The Swiss company began selling its version of the drug in Europe – where it is called Zarzio – in 2009. Novartis also markets two other biosimilar drugs in about 60 countries.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.